Pharmaceutics, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
Amsterdam Institute of Molecular and Life Sciences (AIMMS), Division of Medicinal Chemistry, Faculty of Sciences, VU University , Amsterdam, The Netherlands.
Methods Mol Biol. 2022;2451:505-520. doi: 10.1007/978-1-0716-2099-1_23.
Photosensitizers have recently been conjugated to nanobodies for targeted photodynamic therapy (PDT) to selectively kill cancer cells. The success of this approach relies on nanobody-photosensitizer conjugates that bind specifically to their targets with very high affinities (k in low nM range). Subsequently, upon illumination, these conjugates are very toxic and selective to cells overexpressing the target of interest (EC in low nM range). In this chapter, protocols are described to determine the binding affinity of the nanobody-photosensitizer conjugates and assess the toxicity and selectivity of the conjugates when performing in vitro PDT studies. In addition, and because the efficacy of PDT also depends on the (subcellular) localization of the conjugates at the time of illumination, assays are described to investigate the uptake and the intracellular degradation of the nanobody-photosensitizer conjugates.
最近,已经将光敏剂与纳米抗体偶联用于靶向光动力疗法 (PDT),以选择性地杀死癌细胞。这种方法的成功依赖于纳米抗体-光敏剂缀合物,它们与目标物具有非常高的亲和力(k 在低 nM 范围内)特异性结合。随后,在光照下,这些缀合物对过表达感兴趣的靶标的细胞非常有毒且具有选择性(EC 在低 nM 范围内)。在本章中,描述了确定纳米抗体-光敏剂缀合物的结合亲和力的方案,并评估了在进行体外 PDT 研究时缀合物的毒性和选择性。此外,由于 PDT 的疗效还取决于在光照时缀合物的(亚细胞)定位,因此还描述了用于研究纳米抗体-光敏剂缀合物摄取和细胞内降解的测定法。